7 research outputs found
The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome
Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of controlled patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients
COVID-19 Course in Allergic Asthma Patients: A Spanish Cohort Analysis
COVID-19; Asthma; EosinophilsCOVID-19; Asma; EosinófilosCOVID-19; Asma; EosinòfilsPurpose: The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a high impact on patients with chronic diseases. In the literature, there are different perspectives on asthma as comorbidity or risk factor on COVID-19 severity.
Patients and methods: The aim of this retrospective study across 13 allergy departments in Spain was to determine the severity of COVID-19 in asthmatic adults followed in allergy departments and its relationship with atopy, clinical and demographic characteristics, phenotypes and laboratory data. In addition, lung function test and asthma control test (ACT) before and after COVID-19 were analyzed. Data was obtained from electronic medical records from March 2020 to April 2021.
Results: Two hundred one asthmatic patients were diagnosed with COVID-19 infection by validated detection test. About 30% of the patients were admitted for bilateral pneumonia. Advanced age, elevated D-dimer, lower numbers of lymphocytes and eosinophils, heart diseases and hypertension were associated with severe COVID-19. Allergic and mixed allergic/eosinophilic phenotype and their biomarkers (total IgE, aeroallergens sensitizations, allergic rhinitis, and blood eosinophilia) were related to fewer hospital admissions. Poor control and lower forced expiratory volume in the first second (FEV1) were related to worse prognosis of COVID-19.
Conclusion: Asthmatic patients with allergic and eosinophilic phenotype have a better evolution of COVID-19 and lower risk of admissions. Older patients, cardiovascular comorbidities, AERD and eosinopenia are related to severity COVID-19
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data.
Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. The aim of the present study was to evaluate the effectiveness of add-on reslizumab in a cohort of patients with SEUA under real-life conditions. This was a multi-centre, retrospective, real-life study that included subjects with SEUA treated with reslizumab in 44 asthma units throughout Spain. Eligible patients were those who had received at least one dose of reslizumab as part of normal clinical practice. The primary endpoint was complete asthma control at 52 weeks, defined as absence of severe exacerbations, ACT ≥20 and no maintenance oral corticosteroids (OCS). Demographic, clinical, and functional data were collected at baseline (T0), after four to six months (T1); after 12 months (T2) and beyond 12 months of therapy (T3). Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0-4.0 at V0 to 0.0; IQR: 0.0-0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0-61.6 at T0 to 18.5% (95% CI: 12.5-24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p Reslizumab is an effective therapy for SEUA with adequate safety profile in real-life conditions
COVID-19 Course in Allergic Asthma Patients: A Spanish Cohort Analysis.
The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a high impact on patients with chronic diseases. In the literature, there are different perspectives on asthma as comorbidity or risk factor on COVID-19 severity. The aim of this retrospective study across 13 allergy departments in Spain was to determine the severity of COVID-19 in asthmatic adults followed in allergy departments and its relationship with atopy, clinical and demographic characteristics, phenotypes and laboratory data. In addition, lung function test and asthma control test (ACT) before and after COVID-19 were analyzed. Data was obtained from electronic medical records from March 2020 to April 2021. Two hundred one asthmatic patients were diagnosed with COVID-19 infection by validated detection test. About 30% of the patients were admitted for bilateral pneumonia. Advanced age, elevated D-dimer, lower numbers of lymphocytes and eosinophils, heart diseases and hypertension were associated with severe COVID-19. Allergic and mixed allergic/eosinophilic phenotype and their biomarkers (total IgE, aeroallergens sensitizations, allergic rhinitis, and blood eosinophilia) were related to fewer hospital admissions. Poor control and lower forced expiratory volume in the first second (FEV1) were related to worse prognosis of COVID-19. Asthmatic patients with allergic and eosinophilic phenotype have a better evolution of COVID-19 and lower risk of admissions. Older patients, cardiovascular comorbidities, AERD and eosinopenia are related to severity COVID-19
Additional file 1 of Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study
Supplementary Material
La investigación universitaria y sus contribuciones en Mesoamérica
La Universidad Autónoma de Chiapas a través de su Proyecto Académico 2014-2018, reafirma su compromiso con el desarrollo de nuestra región, al establecer líneas de desarrollo de nuestra región, al establecer líneas de desarrollo institucional, donde la vinculación de la investigación ocupa un lugar preponderante; en este sentido, a partir de 2015, junto con la comunidad académica internacional, se unió a la Agenda 2030 para el Desarrollo sostenible de la ONU y priorizó los 17 Objetivos de Desarrollo Sostenible (ODS) y sus 169 metas, con la finalidad de dar soluciona los grandes desafíos sociales, económicos y medioambientales que enfrenta la sociedad.
Este libro es la recopilación de trabajos realizados por académicos de diversas Instituciones de Educación Superior y Centros de Investigación, de manera multidisciplinaria, interinstitucional e internacional, los cuales han permitido compartir intereses en diversas líneas de generación y aplicación del conocimiento
La investigación universitaria y sus contribuciones en Mesoamérica
La Universidad Autónoma de Chiapas a través de su Proyecto Académico 2014-2018, reafirma su compromiso con el desarrollo de nuestra región, al establecer líneas de desarrollo de nuestra región, al establecer líneas de desarrollo institucional, donde la vinculación de la investigación ocupa un lugar preponderante; en este sentido, a partir de 2015, junto con la comunidad académica internacional, se unió a la Agenda 2030 para el Desarrollo sostenible de la ONU y priorizó los 17 Objetivos de Desarrollo Sostenible (ODS) y sus 169 metas, con la finalidad de dar soluciona los grandes desafíos sociales, económicos y medioambientales que enfrenta la sociedad.
Este libro es la recopilación de trabajos realizados por académicos de diversas Instituciones de Educación Superior y Centros de Investigación, de manera multidisciplinaria, interinstitucional e internacional, los cuales han permitido compartir intereses en diversas líneas de generación y aplicación del conocimiento